key: cord-0852561-5zktvjdo
authors: Grabowski, F.; Kochanczyk, M.; Lipniacki, T.
title: L18F substrain of SARS-CoV-2 VOC-202012/01 is rapidly spreading in England
date: 2021-02-09
journal: nan
DOI: 10.1101/2021.02.07.21251262
sha: d28a2930047f0f2aeb5918a32300b713a6222d6e
doc_id: 852561
cord_uid: 5zktvjdo

The Variant of Concern (VOC)-202012/01 (also known as B.1.1.7) is a rapidly growing lineage of SARS-CoV-2. In January 2021, VOC-202012/01 constituted about 80% of SARS-CoV-2 genomes sequenced in England and was present in 27 out of 29 countries that reported at least 50 viral genomes. As this strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. Based on GISAID data we systematically estimated growth rates of mutations acquired by the lineage to find that L18F substitution in spike initiated a substrain characterized by replicative advantage of 1.70 [95% CI: 1.56-1.96] in relation to the remaining VOC-202012/01 substrains. We also indicate three mutations in the receptor binding motive of spike, that arose in VOC-202012/01: E484K, F490S, S494P, and may give rise to escape mutants. Such mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine induced seroprevalence.

The SARS-CoV-2 Variant of Concern (VOC)-202012/01, also known as B.1.1.7 lineage (first GI-SAID sequence accession ID: EPI_ISL_601443) is characterized by nine spike protein mutations (three deletions: 69H-70V, 145V; and six substitutions: N501Y, A570D, D614G, P681H, T716I, S982A, D1118H). The lineage has started spreading rapidly in mid-October 2020 to constitute about 80% of all SARS-CoV-2 genomes sequenced in England in January 2021. 1, 2 Its spreading capacity may be expressed in terms of its replicative advantage-the ratio of the reproduction numbers of the VOC to the non-VOC strains, R VOC t /R nonVOC t . In such R VOC t /R nonVOC t estimation it is assumed that both the VOC and the non-VOC strains have the same average serial interval of 6.73 days 7 ; then, R VOC t /R nonVOC t = q 6.73/7 V , where q V is the weekly growth of the ratio of the VOC to the non-VOC strains, r V (see Figure 1 ).

The VOC strain, as all strains, continues to mutate. Because of its significant replicative advantage, any accrued mutations are given an opportunity to spread (potentially worldwide), depending on their own replicative advantage with respect to the bulk VOC strain, or higher ability to infect seroprevalent individuals. Here, we focus on spike L18F mutation. The first occurrence of this leucine-to-phenylalanine substitution in residue 18 has been reported in a VOC strain genome collected on December 4, 2020 (GISAID ID: EPI_ISL_720875 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251262 doi: medRxiv preprint Figure 1 : The replicative advantage of the VOC strain. The ratio of the VOC to the non-VOC genomes collected in weeks 38-51 of 2020 in England, r V . Data points are labeled with ratios of the counts of genome sequences. Data aggregated into weeks indicated that r V changes from 30 : 6738 = 0.0045 in week 43 to 4970 : 4054 = 1.23 in week 51, i.e., 275 times, which means that r VOC increases 275 1/8 ≈ 2.02-fold per week. The trend line is fitted to data points for weeks 43-51 (violet) and for weeks 43-47 (pink). The weekly growth rate is 1.92 [95% CI: 1.78-2.08] for weeks 43-51 and 2.35 [95% CI: 2.10-2.62] for weeks 43-47 of 2020. The figure is based on GISAID data submitted till February 5, 2021. The VOC genomes were counted by selecting the B.1.1.7 lineage in GISAID.

February 5, 2021, as much as 850 spike L18F VOC genomes have been reported in England.

Of note, in autumn 2020, that is, before the VOC lineage has become the dominant strain, the spike L18F substitution was an ubiquitous mutation in England. Till February 5, 2021, most of L18F non-VOC genomes in England (97.5%, 25 061 out of 25 712) were found within an A222V strain termed 20A.EU1, that started expanding in England in mid-August 2020 and constituted 63% of genomes sequenced in England in November 2020. 8 The fraction of spike L18F mutation in the expanding 20A.EU1 strain was slowly increasing from 35% (1332 out of 3799) in September, 43% (5658 out of 13 046) in October, till 52% (8917 out of 17 470) in November 2020, which may suggest that this mutation was beneficial for growth of the 20A.EU1 strain. Here, we demonstrate the nearly exponential growth of the spike L18F VOC substrain with respect to L18 VOC strains in the 5-week period of December 7, 2020-January 17, 2021, suggesting its high replicative advantage within the population of England.

In Figure 2 we show the exponential growth of the L18F VOC substrain in England in the five-week period of December 7, 2020-January 17, 2021, in relation to the VOC genomes non-mutated at residue 18, denoted L18. In the considered period, the ratio of L18F to L18 genomes increased with the fitted growth rate of q L = 1.73. If we assume that the L18F VOC 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2021. narrower, which means that nearly perfect co-linearity of five data points is somewhat coincidental, and the binomial distribution-based CI is the proper estimate. This analysis, based on currently very incomplete data, suggests high replication advantage of the L18F VOC substrain in relation to the remaining VOC genomes. This finding is supported by data from Wales, UK, where the L18F VOC genomes constituted 13% (145 out of 1079) of all VOC genomes reported in January, substantially more than in the same period in England, 3% (760 out of 26 174). The number of genomes in Wales is however too small to perform an analysis analogous to that in 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251262 doi: medRxiv preprint selection due to the increasing number of convalescent or immunized individuals. The VOC-202012/01 strain spike RBM mutations of special concern are substitutions E484K and S494P. • S494P. A first genome has been collected on November 12, 2020 (GISAID ID: EPI_ISL_ 741039), and there were 369 genomes reported from the UK up till February 5, 2021. In an in silico study, this substitution has been found to increase complementarity between the RBD and ACE2. 13 This mutation has been also characterized as an escape mutation by Koenig et al., 14 who also distinguished six additional "escape" residues in the RBM: G447, Y449, L452, F490, G496, and five outside the RBM but within the RBD: Y369, S371, T376, F377, K378. Among these residues, until February 5, 2021, substitution F490S (first collected on December 13, 2020, GISAID ID: EPI_ISL_736026) was reported in the highest number of genomes (20 genomes in the UK).

We have shown that the VOC substrain conferring L18F mutation is rapidly growing in the UK. Based on data collected in five-week period of December 7, 2020-January 17, 2021, in 10 Tegally H. et al. (2020 ) medRxiv, 2020 .12.21.20248640. 11 Sabino E. C. et al. (2021 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 England we estimated the replicative advantage of this substrain in relation to the remaining VOC strains as 1.70 [95% CI: 1.56-1.96]. Importantly, L18F mutation has also expanded in the South African strain 501Y.V2 defined by three spike mutations K417N, E484K, N501Y (thus sharing with the VOC strain spike mutation N501Y). Among the 501Y.V2 genomes collected after December 1, 2020, the L18F substrain constitutes 40% genomes (97 out of 243, according to GISAID as of February 5, 2021). In Brazil, in strain P.1 defined by three spike mutations K417T, E484K, N501Y (differing from the South African strain 501Y.V2 by substitution K417T instead of K417N) mutation L18F has been found in 92% of genomes (56 out of 61) collected after December 1, 2020. This data suggests replicative advantage of L18F substrains within the VOC, 501Y.V2, and P.1 strains, in, respectively, England, South Africa, and Brazil.

Our finding must be considered with caution until the mechanism promoting faster spread of strains containing L18F substitution is elucidated. Leucine 18 lies in the N-terminal domain (NTD), that has not been typically considered as a target for neutralizing antibodies (Abs). However, there is a growing number of studies showing that the NTD is targeted by Abs and that NTD deletion 69H-70V (characterizing the VOC strain) compromises binding of Abs 15, [15] . VOC strains, suggests that the replicative advantage of L18F mutants can be partly associated with their ability to infect seroprevalent individuals. In turn, propagation of mutations in escape residues (L18, E484, F490S, or S494) on the VOC strain suggests an increasing selection pressure resulting from the growth of the seroprevalent fraction of the population of England.

This trend can be enhanced by the ongoing English vaccination program, in which the relatively large time span between the first and second dose can be a contributing factor. 15 Kemp S. A. et al. (2020 ) medRxiv, 2020 .12.05.20241927. 16 Cele S. et al. (2021 ) medRxiv, 2021 .01.26.21250224. 17 McCallum M. et al. (2021 ) bioRxiv, 2021 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251262 doi: medRxiv preprint

strain genomes, VOC and non-VOC (in Figure 1) and L18F VOC and L18 VOC

The funding agency had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript

Marek Kochańczyk and Tomasz Lipniacki; Data curation and Software, Frederic Grabowski; Investigation, Frederic Grabowski and Marek Kochańczyk; Supervision, Marek Kochańczyk and Tomasz Lipniacki

Writing -original draft, Tomasz Lipniacki; Writing -review & editing, Marek Kochańczyk. Corresponding authors Correspondence to Tomasz Lipniacki

The authors have no competing interests.

We analyzed publicly available genome datasets retrieved from GISAID, https://www.gisaid.org.